Hostname: page-component-cb9f654ff-hn9fh Total loading time: 0 Render date: 2025-08-24T20:19:21.591Z Has data issue: false hasContentIssue false
  • English
  • Français

Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo

Results of a multicentre study

Published online by Cambridge University Press:  06 August 2018

F. Hohagen ,
G. Winkelmann ,
H. Rasche-Räuchle ,
I. Hand ,
A. König ,
N. Münchau ,
H. Hiss ,
C. Geiger-Kabisch ,
C. Käppler  and
P. Schramm
...Show all authors
F. Hohagen*
Affiliation:
Department of Psychiatry and Psychotherapy, University of Freiburg
G. Winkelmann
Affiliation:
Department of Psychiatry and Psychotherapy, University of Freiburg
H. Rasche-Räuchle
Affiliation:
Department of Psychiatry and Psychotherapy, University of Freiburg
I. Hand
Affiliation:
Department of Psychiatry, University of Hamburg
A. König
Affiliation:
Department of Psychiatry, University of Hamburg
N. Münchau
Affiliation:
Department of Psychiatry, University of Hamburg
H. Hiss
Affiliation:
Department of Psychiatry, University of Hamburg
C. Geiger-Kabisch
Affiliation:
Central Institute of Mental Health, Mannheim
C. Käppler
Affiliation:
Department of Psychiatry and Psychotherapy, University of Freiburg
P. Schramm
Affiliation:
Department of Psychiatry and Psychotherapy, University of Freiburg
E. Rey
Affiliation:
Central Institute of Mental Health, Mannheim
J. Aldenhoff
Affiliation:
Department of Psychiatry, University of Kiel
M. Berger
Affiliation:
Department of Psychiatry and Psychotherapy, University of Freiburg
*
Correspondence: Dr Fritz Hohagen, Psychiatric Department of the University of Freiburg, Hauptstr. 5, 79104 Freiburg, Germany. Tel: +49 761–270-6521/6518. Fax: +49 761–270-6523
Get access Rights & Permissions [Opens in a new window]

Abstract

Background We investigated whether the combination of multimodal behaviour therapy (BT) with fluvoxamine is superior to BTand placebo in the acute treatment of severely ill in-patients with obsessive-compulsive disorder (OCD).

Method In a randomised, double-blind design, 30 patients were treated for nine weeks with BT plus placebo and 30 patients with BT plus fluvoxamine (maximum dosage 300 mg, mean dose 288.1 mg). BT included exposure with response prevention, cognitive restructuring and development of alternative behaviours.

Results Both groups showed a highly significant symptom reduction after treatment. There were no significant differences between the groups concerning compulsions. Obsessions were significantly more reduced in the fluvoxamine and BT group than in the placebo and BT group. Furthermore, the group BT plus fluvoxamine showed a significantly higher response rate (87.5 v. 60%) according to a previously defined response criterion. Severely depressed patients with OCD receiving BT plus placebo presented a significantly worse treatment outcome (Y–BOCS scores) than all other groups.

Conclusions The results suggest that BTshould be combined with fluvoxamine when obsessions dominate the clinical picture and when a secondary depression is present.

Information

Type
Research Article
Information
The British Journal of Psychiatry , Volume 173 , Issue S35: New perspectives in research and treatment of obsessive-compulsive disorder , August 1998 , pp. 71 - 78
Copyright
Copyright © 1998 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Abel, J. L. (1993) Exposure with response prevention and serotonergic antidepressants in the treatment of obsessive-compulsive disorder: a review and implications for interdisciplinary treatment. Behaviour Research and Therapy, 31, 463–478.CrossRefGoogle ScholarPubMed
American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM-111-R). Washington, DC: APA.Google Scholar
Arts, W., Hoogduin, K., Schaap, C., et al (1993) Do patients suffering from obsessions alone differ from other obsessive compulsions? Behaviour Research and Therapy, 31, 119–123.CrossRefGoogle Scholar
Ball, S. G., Baer, L. & Otto, M. W. (1996) Symptom subtypes of obsessive-compulsive disorder in behavioral treatment studies: a quantitative review. Behaviour Research and Therapy, 34, 47–51.CrossRefGoogle ScholarPubMed
Basoglu, M., Lax, T., Kasvikis, Y., et al (1988) Patterns and predictors of improvement in obsessive-compulsive disorder. Journal of Anxiety Disorders, 2, 299–317.CrossRefGoogle Scholar
Christensen, H., Hadzi-Pavlovic, D., Andrews, G., et al (1987) Behavior therapy and tricyclic medication in the treatment of obsesive-compulsive disorder: a quantitative review. Journal of Consulting and Clinical Psychology, 55, 701–711.CrossRefGoogle Scholar
Cottraux, J., Mollard, E., Bouvard, M., et al (1990) A controlled study of fluvoxamine and exposure in obsessive compulsive disorder. International Clinical Psychopharmacology, S, 17–30.CrossRefGoogle Scholar
Cottraux, J., Mollard, E., Bouvard, M., et al (1993) Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: one-year follow-up. Psychiatry Research, 49, 63–75.CrossRefGoogle ScholarPubMed
Derogatis, L. R., Lipman, R. S. & Covi, L. (1976) SCL-90. Self-report symptom inventory. In ECDEU Assessment Manual for Psychopharmacology (ed. Guy, W.), pp. 313–331. Rockville, MD: National Institute of Mental Health.Google Scholar
Foa, E. B., Grayson, J. B. & Steketee, G. (1982) Depression, habituation and treatment outcome in obsessive-compulsives. In Practical Applications of Learning Theories in Psychiatry (ed. Boulougouris, J. C.). New York: Wiley.Google Scholar
Foa, E. B., Kozak, M. J., Steketee, G., et al (1992) Treatment of depressive and obsessive-compulsive symptoms in OCD by imipramine and behavior therapy. British Journal of Clinical Psychology, 31, 279–292.CrossRefGoogle Scholar
Foa, E. B., Kozak, M. J. (1996) Psychological treatment for obsessive-compulsive disorder. In Long-Term Treatment of Anxiety Disorders (eds Mavissakalian, M. R. & Prien, R. F.), pp. 285–309. Washington, DC: American Psychiatric Press.Google Scholar
Franke, G. (1995) SCL-90-R – Die Symptom-Checkliste von Derogates. Weinheim: Beltz.Google Scholar
Goodman, W. K., Price, L. H., Rasmussen, S. A., et al (1989) The Yale-Brown Obsessive Compulsive Scale. Development, use and reliability. Validity. Archives of General Psychiatry, 46, 1006–1016.CrossRefGoogle Scholar
Hamilton, M. (1960) A rating scale for depression. Journal of Neurological and Neurosurgical Psychiatry, 23, 56–62.CrossRefGoogle ScholarPubMed
Hand, I. & Büttner-Westphal, H. (1991) Die Yale-Brown Obsessive Compulsive Scale (Y-BOCS): Ein halbstrukturiertes Interview zur Beurteilung des Schweregrades von Denk-und Handlungszwä ngne. Werhaltenstherapie, 1, 223–233.CrossRefGoogle Scholar
Hoogduin, K., de Haan, E., Schaap, C., et al (1987) Exposure and response prevention in patients with obsessions. Acta Psychiatrica belgica, 87, 640–653.Google ScholarPubMed
Kasvikis, Y. & Marks, I. (1988) Clomipramine, self-exposure and therapist aided exposure in obsessive-compulsive ritualizers: II. Two year follow up. Journal of Anxiety Disorders, 2, 291–298.CrossRefGoogle Scholar
Marks, I. (1987) Fears, Phobias and Rituals. Oxford: Oxford University Press.Google Scholar
Marks, I., Stern, R. S., Mawson, D., et al (1980) Clomipramine and exposure for obsessive-compulsive rituals. British Journal of Psychiatry, 136, 1–25.CrossRefGoogle ScholarPubMed
Marks, I. & O'Sullivan, G. (1988) Drugs and psychological treatments for agoraphobia/panic and obsessive-compulsive disorder: a review. British Journal of Psychiatry, 153, 650–658.CrossRefGoogle Scholar
Marks, I., Lelliott, P., Basoglu, M., et al (1988) Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive rituals. British Journal of Psychiatry, 152, 522–534.CrossRefGoogle ScholarPubMed
Mawson, D., Marks, I. & Ramm, L. (1982) Clomipramine and exposure for chronic obsessive-compulsive rituals: III. Two-year follow-up and further findings. British Journal of Psychiatry, 140, 11–18.CrossRefGoogle ScholarPubMed
McDougle, C. J., Goodman, W. K., Leckmann, J. F., et al (1994) Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. Archives of General Psychiatry, 51, 302–308.CrossRefGoogle ScholarPubMed
National Institute of Mental Health (1976) 028 CGI. Clinical Global Impressions. In Manual for the EDCEU Assessment Battery (2nd edn, revised) (eds Guy, W. & Bonato, R. R.), pp. 12–1–12–6. Maryland: Chevy Chase.Google Scholar
O'Sullivan, G. & Marks, I. (1990) Long term follow up of Phobic and Obsessive-Compulsive Disorder. In Handbook of Anxiety: The Treatment of Anxiety: Vol. 4 (eds Noves, R., Roth, M. & Burrows, G.), pp. 88–108. Amsterdam: Elsevier.Google Scholar
Perse, T. (1988) Obsessive-compulsive disorder: a treatment review. Journal of Clinical Psychiatry, 49, 48–55.Google ScholarPubMed
Salkovskis, P. M. (1989) Obsessions and compulsions. In Cognitive Therapy in Clinical Practice. An Illustrative Casebook (eds Scott, J., Williams, J. M. G. & Beck, A. T.), pp. 50–77. London: Routledge.Google Scholar
Salkovskis, P. M. & Westbrook, D. (1989) Behavior therapy and obsessional ruminations: Can failure be turned into success? Behaviour Research and Therapy, 27, 149–160.CrossRefGoogle ScholarPubMed
Snaith, R. P., Baugh, S. J., Clyden, A. D., et al (1982) The Clinical Anxiety Scale: an instrument derived from Hamilton Anxiety Scale. British Journal of Psychiatry, 141, 518–523.CrossRefGoogle ScholarPubMed
Solyom, L. & Sookman, D. (1977) A comparison of clomipramine hydrochloride (Anafranil) and behavior therapy in the treatment of obsessive-compulsive neurosis. Journal of International Medical Research, 5 (suppl. 5), 49–61.Google Scholar
Spitzer, R. L., Williams, J. B. & Gibbsons, M. (1984) The Structured Clinical Interview for DSM-111-R. Biometrie Research Department. New York: New York State Psychiatric Institute.Google Scholar
Spitzer, R. L., Williams, J. B. & Gibbsons, M. (1987) Structured Clinical Interview for DSM-111-R (SCID II). New York: New York State Psychiatric Institute.Google Scholar
Stern, R., Marks, I., Mawson, D., et al (1980) Clomipramine and exposure for compulsive rituals: II. Plasma levels, side effects and outcome. British Journal of Psychiatry, 136, 161–166.CrossRefGoogle ScholarPubMed
Wittchen, H. U., Zaudig, M., Schramm, E., et al (1988) Strukturiertes klinisches Interview für DSM-111-R (SKID). Weinheim: Beltz.Google Scholar
Wittchen, H. U., Schramm, E., Zaudig, M., et al (1992) Strukturiertes klinisches Interview DSM-111-R Achse II (Persönlichkeitsstörungen). München: Max Plank Institut.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.